Compare Medpace Holdings Inc (MEDP) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Schwab US Large Cap Growth ETF — how do they compare? Medpace Holdings Inc trades at $532.42 (market cap $15.08B), while Schwab US Large Cap Growth ETF trades at $34.26. The key difference: Schwab US Large Cap Growth ETF is trading nearer its 52-week high, Medpace Holdings Inc nearer its low. Which is the better fit depends on your goals.
| MEDP | SCHG | |
|---|---|---|
Market Cap | $15.08B | — |
Sector | Technology | Sector/Thematic |
52-Week High | $620.59 | $35.30 |
52-Week Low | $308.88 | $28.10 |
Enterprise Value | $14.55B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
SCHG trades at $34.15, down slightly by 0.09% today, with a bullish technical signal driven by moving averages. The ETF offers concentrated exposure to large-cap U.S. growth stocks, particularly in technology and AI, with a low 0.04% expense ratio. Recent news highlights strong fundamentals and AI-driven growth potential, though heavy concentration in top holdings like Nvidia, Apple, and Microsoft presents both opportunity and risk.
Outlook remains positive for long-term growth investors, supported by AI capital expenditure trends and low costs. Key risks include high valuation sensitivity, interest rate impacts, and lack of diversification. Analyst sentiment is mixed, with some caution on recent underperformance versus broader markets despite strong thematic tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
